UROVANT-SCIENCES
5.7.2022 14:07:11 CEST | Business Wire | Press release
Urovant Sciences , a wholly-owned subsidiary of Sumitovant Biopharma Ltd., and Pierre Fabre Médicament today announced they have entered into an exclusive license agreement for Pierre Fabre to register and commercialize vibegron for the treatment of Overactive Bladder (OAB) in the European Economic Area, UK, and Switzerland, with some option territories, which notably include French-speaking countries of Sub-Saharan Africa, Turkey, and certain Eastern European countries. Urovant will retain full rights in the United States and other select markets.
“We are thrilled to partner with Pierre Fabre, a leader in the international biopharmaceutical space,” said Jim Robinson, Chief Executive Officer of Urovant Sciences. “Their experience in the global OAB and Benign Prostatic Hyperplasia (BPH) market make them uniquely suited to deliver vibegron to more patients who need it across Europe and surrounding areas.”
Under the terms of the agreement, Urovant Sciences will receive payments up to USD $75 million, based on upfront, regulatory, and sales milestone payments. Additionally, Urovant will receive royalties based on sales performance.
Urovant Sciences and Pierre Fabre will share responsibility for vibegron clinical trials in the pediatric populations in Europe. As part of the transaction, Urovant Sciences will also provide manufacturing services to Pierre Fabre.
“We are delighted to enter into this partnership with Urovant, which will bring effective treatment and improved quality of life to all patients suffering from Overactive Bladder (OAB) in Europe. This partnership confirms Pierre Fabre's extensive expertise in urology and in women's health for five decades and the group's ambitions to offer therapeutic solutions to chronic diseases that are very disabling in everyday life,” said Eric Ducournau, group CEO at Pierre Fabre.
About Overactive Bladder
Overactive bladder (OAB) is a clinical condition that occurs when the bladder muscle contracts involuntarily. Symptoms may include urinary urgency (the sudden urge to urinate that is difficult to control), urgency incontinence (unintentional loss of urine immediately after an urgent need to urinate), frequent urination (usually eight or more times in 24 hours), and nocturia (waking up more than two times in the night to urinate).1
While 33 million US adults experience the bothersome symptoms of OAB, approximately 546 million people ≥ 20 years are affected by OAB worldwide. 1,2
About Urovant Sciences
Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for areas of unmet need, with a dedicated focus in Urology. The Company’s lead product, GEMTESA® (vibegron), is an oral, once-daily (75 mg) small molecule beta-3 agonist for the treatment of adult patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. GEMTESA was approved by the U.S. FDA in December 2020 and launched in the U.S. in April 2021. GEMTESA is also being evaluated for the treatment of OAB in men with benign prostatic hyperplasia. The Company’s second product candidate, URO-902, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy. Urovant Sciences, a wholly owned subsidiary of Sumitovant Biopharma Ltd., intends to bring innovation to patients in need in urology and other areas of unmet need. Learn about us at www.urovant.com or follow us on Twitter or LinkedIn .
About Sumitovant Biopharma
Sumitovant is a technology-driven biopharmaceutical company accelerating development of new potential therapies for patients with high unmet medical need. Through our company portfolio and use of embedded computational technology platforms to generate business and scientific insights, Sumitovant has supported development of FDA-approved products and advanced a promising pipeline of early-through late-stage investigational assets for other serious conditions. Sumitovant’s subsidiary portfolio includes wholly owned Enzyvant, Urovant, Spirovant and Altavant, and majority owned Myovant (NYSE: MYOV). Sumitomo Pharma is Sumitovant’s parent company. For more information, please visit www.sumitovant.com .
About Pierre Fabre Group
Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world, the 2nd largest private French pharmaceutical group and the market leader in France for products sold over the counter in pharmacies. Its portfolio includes several medical franchises and international brands including Pierre Fabre Oncology, Pierre Fabre Dermatology, Eau Thermale Avène, Klorane, Ducray, René Furterer, A-Derma, Naturactive, Pierre Fabre Oral Care.
In 2021, Pierre Fabre generated €2.5 billion in revenues, 66% of which came from international sales. Established in the South-West of France since its creation, the Group manufactures over 95% of its products in France and employs some 9,500 people worldwide. Its products are distributed in about 115 countries. Pierre Fabre is 86%-owned by the Pierre Fabre Foundation, a government-recognized public-interest foundation, and secondarily by its own employees through an international employee stock ownership plan.
To learn more, please go to https://www.pierre-fabre.com/en . You can also join us on Twitter at @PierreFabre and Facebook at www.facebook.com/laboratoirespierrefabre .
About GEMTESA® tablets for oral use (US market)
GEMTESA® is a prescription medicine for adults used to treat the following symptoms due to a condition called overactive bladder:
- urge urinary incontinence: a strong need to urinate with leaking or wetting accidents
- urgency: the need to urinate right away
- frequency: urinating often
It is not known if GEMTESA is safe and effective in children.
IMPORTANT SAFETY INFORMATION
Do not take GEMTESA if you are allergic to vibegron or any of the ingredients in GEMTESA.
Before you take GEMTESA, tell your doctor about all your medical conditions, including if you have liver problems; have kidney problems; have trouble emptying your bladder or you have a weak urine stream; take medicines that contain digoxin; are pregnant or plan to become pregnant (it is not known if GEMTESA will harm your unborn baby; talk to your doctor if you are pregnant or plan to become pregnant); are breastfeeding or plan to breastfeed (it is not known if GEMTESA passes into your breast milk; talk to your doctor about the best way to feed your baby if you take GEMTESA).
Tell your doctor about all the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.
What are the possible side effects of GEMTESA?
GEMTESA may cause serious side effects including the inability to empty your bladder (urinary retention). GEMTESA may increase your chances of not being able to empty your bladder, especially if you have bladder outlet obstruction or take other medicines for treatment of overactive bladder. Tell your doctor right away if you are unable to empty your bladder. The most common side effects of GEMTESA include headache, urinary tract infection, nasal congestion, sore throat or runny nose, diarrhea, nausea, and upper respiratory tract infection. These are not all the possible side effects of GEMTESA. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Please click here for full Product Information for GEMTESA.
References:
1.
Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int
. 2011;108(7):1132-1138. doi:10.1111/j.1464-410X.2010.09993.x
2.
Leron E, Weintraub AY, Mastrolia SA, Schwarzman P. Overactive bladder syndrome: evaluation and management. Curr Urol
. 2017;11:117-125. doi:10.1159/000447205
UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries. All other trademarks are the property of their respective owners. © 2022 Urovant Sciences. All rights reserved.
PIERRE FABRE, the PIERRE FABRE logo are trademarks of Pierre Fabre Medicament SAS, registered in the U.S and in other countries. All other trademarks are the property of their respective owners. © 2022 Pierre Fabre Medicament. All right reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005255/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Navan Selected by Investec to Modernize Global Travel Program12.10.2026 10:00:00 CEST | Press release
Leading international bank and wealth manager chooses Navan to deliver an AI-first travel program Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Investec, a leading international bank and wealth manager, to upgrade its global travel program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009977645/en/ Leading international bank and wealth manager chooses Navan to deliver an AI-first travel program “As Investec continues its digital transformation, we’re excited to partner with an AI-first travel platform to increase adoption and improve operational efficiency,” said Lyndon Subroyen, Investec Group Chief Technology and Operating Officer. As a dual-listed company in the United Kingdom and South Africa, Investec sought a partner to consolidate its travel operations, reduce administrative work, and improve the booking experience for its workforce. Inve
Opensignal Launches World’s First Interactive Map of Satellite-to-Smartphone D2D Connections12.10.2026 10:00:00 CEST | Press release
Provides Independent, Real-World Global View of Direct-to-Device Activity Opensignal, a global independent consumer connectivity analytics and insights company, today launched the Opensignal D2D Satellite Map, the world’s first interactive, real-world depiction of where direct-to-device (D2D) satellite connections with smartphones are happening across the globe. Every point on the map, which will be updated monthly, represents a location where smartphones have connected to a D2D service since January 2026, extracted from Opensignal’s billions of real-world measurements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261011884935/en/ Opensignal D2D Satellite Map “D2D is reshaping who can deliver mobile coverage, and where, because the phone in your pocket can now reach a satellite directly. Until now, the industry has had to make decisions without knowing where momentum and adoption are real,” said Mike Sandy, President, Mark
Demand for Tech Services in Europe Continues to Surge, Led by AI-Driven Infrastructure Spending in Q3: ISG Index™12.10.2026 10:00:00 CEST | Press release
Combined market up 56%, as infrastructure spend more than doublesManaged services up 12%, as enterprises look for savings to fund AI Surging AI demand propelled Europe’s technology services market to a new high in the third quarter, as infrastructure spending more than doubled and traditional managed services grew by double digits, the latest state-of-the-industry report from Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm, finds. The EMEA ISG Index™, which measures commercial outsourcing contracts with annual contract value (ACV) of US $5 million or more, shows third-quarter ACV for the combined market (both managed services and cloud-based infrastructure and software services) soared 56 percent—its fastest growth in eight years—to US $14.9 billion. It was the fourth straight quarter that combined ACV growth has exceeded 20 percent, averaging 39 percent in that span. “The European market is absolutely roaring right now,” said
Carta Secures Authorization to Operate as Fund Administrator and Transfer Agent in Luxembourg12.10.2026 10:00:00 CEST | Press release
The connected platform for private capital adds licensed fund administration and transfer agency to an ERP suite built for Luxembourg fund managers Carta, the connected platform and AI-native ecosystem for private capital, today announced it has received authorization to operate as a fully-licensed Specialised Professional of the Financial Sector (PSF) under the supervision of the CSSF (Commission de Surveillance du Secteur Financier) in Luxembourg. The authorization covers five statutory functions — registrar agent, corporate domiciliation agent, company incorporation and management services, administrative agent of the financial sector, and client communication agent — adding licensed fund administration and transfer agency directly to a platform already serving Luxembourg fund managers. Luxembourg is the second-largest fund domicile in the world, home to approximately 5,000 alternative investment fund entities managing over €1 trillion in assets. It is also the preferred jurisdictio
CIG to Showcase How Next-Generation Broadband Is Driving More Value with PON, Wi-Fi, Optics, and Edge AI at Network X 2026, Booth C4.12.10.2026 09:11:00 CEST | Press release
From a full line of Wi‑Fi 8 Products to industrial Edge AI, CIG will demonstrate technologies designed to create more value across the network Cambridge Industries Group (CIG), a global leader in broadband and optical connectivity technologies, will showcase its latest broadband, optical, and Edge AI platform innovation at Network X 2026, October 13-15 in Vienna. The exhibit will focus on a practical challenge for network operators: how to increase capacity while improving the experience. CIG’s broadband showcase will span the network from fiber access to the connected home. Visitors will see live demonstrations of Wi-Fi 8 capabilities in an XGS-PON gateway, previewing CIG’s approach to next-generation Wi-Fi: greater flexibility in platform design and more dependable performance in real-world subscriber environments. CIG will also demonstrate its prplWare 4.2.1-certified Wi-Fi 7 device. CIG will also showcase the AIU-100 Edge AI controller, initially focused on manufacturing applicatio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom